AUTHOR AND EDITOR INFORMATION

Section 1 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

INTRODUCTION

Section 2 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Background

Rhinitis is defined as inflammation of the nasal membranes¹ and is characterized by a symptom complex that consists of any combination of the following: sneezing, nasal congestion, nasal itching, and rhinorrhea. The eyes, ears, sinuses, and throat can also be involved. Allergic rhinitis is the most common cause of rhinitis. It is an extremely common condition, affecting approximately 20% of the population. While allergic rhinitis is not a life-threatening condition, complications can occur and the condition can significantly impair quality of life, which leads to a number of indirect costs. The total direct and indirect cost of allergic rhinitis was recently estimated to be $5.3 billion per year.

Pathophysiology

Allergic rhinitis involves inflammation of the mucous membranes of the nose, eyes, eustachian tubes, middle ear, sinuses, and pharynx. The nose invariably is involved, and the other organs are affected in certain individuals. Inflammation of the mucous membranes is characterized by a complex interaction of inflammatory mediators but ultimately is triggered by an immunoglobulin E (IgE)–mediated response to an extrinsic protein.

The tendency to develop allergic, or IgE-mediated, reactions to extrinsic allergens (proteins capable of causing an allergic reaction) has a genetic component. In susceptible individuals, exposure to certain foreign proteins leads to allergic sensitization, which is characterized by the production of specific IgE directed against these proteins. This specific IgE coats the surface of mast cells, which are present in the nasal mucosa. When the specific protein (eg, a specific pollen grain) is inhaled into the nose, it can bind to the IgE on the mast cells, leading to immediate and delayed release of a number of mediators.

The mediators that are immediately released include histamine, tryptase, chymase, kinins, and heparin. The mast cells quickly synthesize other mediators, including leukotrienes and prostaglandin D2. These mediators, via various interactions, ultimately lead to the symptoms of rhinorrhea (ie, nasal congestion, sneezing, itching, redness, tearing, swelling, ear pressure, postnasal drip). Mucous glands are stimulated, leading to increased secretions. Vascular permeability is increased, leading to plasma exudation. Vasodilation occurs, leading to congestion and pressure. Sensory nerves are stimulated, leading to sneezing and itching. All of these events can occur in minutes; hence, this reaction is called the early, or immediate, phase of the reaction.

Over 4-8 hours, these mediators, through a complex interplay of events, lead to the recruitment of other inflammatory cells to the mucosa, such as neutrophils, eosinophils, lymphocytes, and macrophages. This results in continued inflammation, termed the late-phase response. The symptoms of the late-phase response are similar to those of the early phase, but less sneezing and itching and more congestion and mucus production tend to occur. The late phase may persist for hours or days.

Systemic effects, including fatigue, sleepiness, and malaise, can occur from the inflammatory response. These symptoms often contribute to impaired quality of life.

Frequency

United States

Allergic rhinitis affects approximately 40 million people in the United States. Recent US figures suggest a 20% cumulative prevalence rate.

International

Scandinavian studies have demonstrated a cumulative prevalence rate of 15% in men and 14% in women. The prevalence of allergic rhinitis may vary within and among countries. This may be due to geographic differences in the types and potency of different allergens and the overall aeroallergen burden.

Mortality/Morbidity

While allergic rhinitis itself is not life-threatening (unless accompanied by severe asthma or anaphylaxis), morbidity from the condition can be significant. Allergic rhinitis often coexists with other disorders, such as asthma, and may be associated with asthma exacerbations. It is also associated with otitis media, eustachian tube dysfunction, sinusitis, nasal polyps, allergic conjunctivitis, and atopic dermatitis. Allergic rhinitis may also contribute to learning difficulties, sleep disorders, and fatigue.

• A number of complications that can lead to increased morbidity or even mortality can occur secondary to allergic rhinitis. Possible complications include otitis media, eustachian tube dysfunction, acute sinusitis, and chronic sinusitis.
• Allergic rhinitis can be associated with a number of comorbid conditions, including asthma, atopic dermatitis, and nasal polyps. Evidence now suggests that uncontrolled allergic rhinitis can actually worsen the inflammation associated with asthma or atopic dermatitis. This could lead to further morbidity and even mortality.
• Allergic rhinitis can frequently lead to significant impairment of quality of life. Symptoms such as fatigue, drowsiness (due to the disease or to medications), and malaise can lead to impaired work and school performance, missed school or work days, and traffic accidents. The overall cost (direct and indirect) of allergic rhinitis was recently estimated to be $5.3 billion per year.

Race

Allergic rhinitis occurs in persons of all races. Prevalence of allergic rhinitis seems to vary among different populations and cultures, which may be due to genetic differences, geographic factors or environmental differences, or other population-based factors.

Sex

In childhood, allergic rhinitis is more common in boys than in girls, but in adulthood, the prevalence is approximately equal between men and women.

Age

Onset of allergic rhinitis is common in childhood, adolescence, and early adult years, with a mean age of onset 8-11 years, but allergic rhinitis may occur in persons of any age. In 80% of cases, allergic rhinitis develops by age 20 years. The prevalence of allergic rhinitis has been reported to be as high as 40% in children, subsequently decreasing with age. In the geriatric population, rhinitis is less commonly allergic in nature.

CLINICAL

Section 3 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

History

Obtaining a detailed history is important in the evaluation of allergic rhinitis. Important elements include an evaluation of the nature, duration, and time course of symptoms; possible triggers for symptoms; response to medications; comorbid conditions; family history of allergic diseases; environmental exposures; occupational exposures; and effects on quality of life. A thorough history may help identify specific triggers, suggesting an allergic etiology for the rhinitis.

Symptoms that can be associated with allergic rhinitis include sneezing, itching (of nose, eyes, ears, palate), rhinorrhea, postnasal drip, congestion, anosmia, headache, earache, tearing, red eyes, eye swelling, fatigue, drowsiness, and malaise.

• Symptoms and chronicity
• • Determine the age of onset of symptoms and whether symptoms have been present continuously since onset. While the onset of allergic rhinitis can occur well into adulthood, most patients develop symptoms by age 20 years.
  • Determine the time pattern of symptoms and whether symptoms occur at a consistent level throughout the year (ie, perennial rhinitis), only occur in specific seasons (ie, seasonal rhinitis), or a combination of the two. During periods of exacerbation, determine whether symptoms occur on a daily basis or only on an episodic basis. Determine whether the symptoms are present all day or only at specific times during the day. This information can help suggest the diagnosis and determine possible triggers.
  • Determine which organ systems are affected and the specific symptoms. Some patients have exclusive involvement of the nose, while others have involvement of multiple organs. Some patients primarily have sneezing, itching, tearing, and watery rhinorrhea (the classic hayfever presentation), while others may only complain of congestion. Significant complaints of congestion, particularly if unilateral, might suggest the possibility of structural obstruction, such as a polyp, foreign body, or deviated septum.
• Trigger factors
• • Determine whether symptoms are related temporally to specific trigger factors. This might include exposure to pollens outdoors, mold spores while doing yard work, specific animals, or dust while cleaning the house.
  • Irritant triggers such as smoke, pollution, and strong smells can aggravate symptoms in a patient with allergic rhinitis. These are also common triggers of vasomotor rhinitis. Many patients have both allergic rhinitis and vasomotor rhinitis.
  • Other patients may describe year-round symptoms that do not appear to be associated with specific triggers. This could be consistent with nonallergic rhinitis, but perennial allergens, such as dust mite or animal exposure, should also be considered in this situation. With chronic exposure and chronic symptoms, the patient may not be able to associate symptoms with a particular trigger.
• Response to treatment
• • Response to treatment with antihistamines supports the diagnosis of allergic rhinitis, although sneezing, itching, and rhinorrhea associated with nonallergic rhinitis can also improve with antihistamines.
  • Response to intranasal corticosteroids supports the diagnosis of allergic rhinitis, although some cases of nonallergic rhinitis (particularly the nonallergic rhinitis with eosinophils syndrome [NARES]) also improve with nasal steroids.
• Comorbid conditions
• • Patients with allergic rhinitis may have other atopic conditions such as asthma or atopic dermatitis. Of patients with allergic rhinitis, 20% also have symptoms of asthma. Uncontrolled allergic rhinitis may cause worsening of asthma or even atopic dermatitis. Explore this possibility when obtaining the patient history.
  • Look for conditions that can occur as complications of allergic rhinitis. Sinusitis occurs quite frequently. Other possible complications include otitis media, sleep disturbance or apnea, dental problems (overbite), and palatal abnormalities. The treatment plan might be different if one of these complications is present. Nasal polyps occur in association with allergic rhinitis, although whether allergic rhinitis actually causes polyps remains unclear. Polyps may not respond to medical treatment and might predispose a patient to sinusitis or sleep disturbance (due to congestion).
  • Investigate past medical history, including other current medical conditions. Diseases such as hypothyroidism or sarcoidosis can cause nonallergic rhinitis. Concomitant medical conditions might influence the choice of medication.
• Family history
• • Because allergic rhinitis has a significant genetic component, a positive family history for atopy makes the diagnosis more likely.
  • In fact, a greater risk of allergic rhinitis exists if both parents are atopic than if one parent is atopic. However, the cause of allergic rhinitis appears to be multifactorial, and a person with no family history of allergic rhinitis can develop allergic rhinitis.
• Environmental and occupational exposure
• • A thorough history of environmental exposures helps to identify specific allergic triggers. This should include investigation of risk factors for exposure to perennial allergens (eg, dust mites, mold, pets). Risk factors for dust mite exposure include carpeting, heat, humidity, and bedding that does not have dust mite–proof covers. Chronic dampness in the home is a risk factor for mold exposure. A history of hobbies and recreational activities helps determine risk and a time pattern of pollen exposure.
  • Ask about the environment of the workplace or school. This might include exposure to ordinary perennial allergens (eg, mites, mold, pet dander) or unique occupational allergens (eg, laboratory animals, animal products, grains and organic materials, wood dust, latex, enzymes).
• Effects on quality of life
• • An accurate assessment of the morbidity of allergic rhinitis cannot be obtained without asking about the effects on the patient's quality of life. Specific validated questionnaires are available to help determine effects on quality of life.^{2, 3}
  • Determine the presence of symptoms such as fatigue, malaise, drowsiness (which may or may not be related to medication), and headache.
  • Investigate sleep quality and ability to function at work.

Physical

The physical examination should focus on the nose, but examination of facial features, eyes, ears, oropharynx, neck, lungs, and skin is also important. Look for physical findings that may be consistent with a systemic disease that is associated with rhinitis.

• General facial features
• • "Allergic shiners" are dark circles around the eyes and are related to vasodilation or nasal congestion.
  • "Nasal crease" is a horizontal crease across the lower half of the bridge of the nose that is caused by repeated upward rubbing of the tip of the nose by the palm of the hand (ie, the "allergic salute").
• Nose
• • The nasal examination is best accomplished with a nasal speculum or an otoscope with nasal adapter. In the specialist's office, a rigid or flexible rhinolaryngoscope may be used.
  • The mucosa of the nasal turbinates may be swollen (boggy) and have a pale, bluish-gray color. Some patients may have predominant erythema of the mucosa, which can also be observed with rhinitis medicamentosa, infection, or vasomotor rhinitis. While pale, boggy, blue-gray mucosa is typical for allergic rhinitis, mucosal examination findings cannot definitively distinguish between allergic and nonallergic causes of rhinitis.
  • Assess the character and quantity of nasal mucus. Thin and watery secretions are frequently associated with allergic rhinitis, while thick and purulent secretions are usually associated with sinusitis; however, thicker, purulent, colored mucus can also occur with allergic rhinitis.
  • Examine the nasal septum to look for any deviation or septal perforation, which may be present due to chronic rhinitis, granulomatous disease, cocaine abuse, prior surgery, topical decongestant abuse, or, rarely, topical steroid overuse.
  • Examine the nasal cavity for other masses such as polyps or tumors. Polyps are firm gray masses that are often attached by a stalk, which may not be visible. After spraying a topical decongestant, polyps do not shrink, while the surrounding nasal mucosa does shrink.
• Ears, eyes, and oropharynx
• • Perform otoscopy to look for tympanic membrane retraction, air-fluid levels, or bubbles. Performing pneumatic otoscopy can be considered to look for abnormal tympanic membrane mobility. These findings can be associated with allergic rhinitis, particularly if eustachian tube dysfunction or secondary otitis media is present.
  • Ocular examination may reveal findings of injection and swelling of the palpebral conjunctivae, with excess tear production. Dennie-Morgan lines (prominent creases below the inferior eyelid) are associated with allergic rhinitis.
  • The term "cobblestoning" is used to describe streaks of lymphoid tissue on the posterior pharynx, which is commonly observed with allergic rhinitis. Tonsillar hypertrophy can also be observed. Malocclusion (overbite) and a high-arched palate can be observed in patients who breathe from their mouths excessively.
• Neck: Look for evidence of lymphadenopathy or thyroid disease.
• Lungs: Look for the characteristic findings of asthma.
• Skin: Evaluate for possible atopic dermatitis.
• Other: Look for any evidence of systemic diseases that may cause rhinitis (eg, sarcoidosis, hypothyroidism, immunodeficiency, ciliary dyskinesia syndrome, other connective tissue diseases).

Causes

The causes of allergic rhinitis may differ depending on whether the symptoms are seasonal, perennial, or sporadic/episodic. Some patients are sensitive to multiple allergens and can have perennial allergic rhinitis with seasonal exacerbations. While food allergy can cause rhinitis, particularly in children, it is rarely a cause of allergic rhinitis in the absence of gastrointestinal or skin symptoms.

• Seasonal allergic rhinitis is commonly caused by allergy to seasonal pollens and outdoor molds.
• • Pollens (tree, grass, and weed)
    • Tree pollens, which vary by geographic location, are typically present in high counts during the spring, although some species produce their pollens in the fall. Common tree families associated with allergic rhinitis include birch, oak, maple, cedar, olive, and elm.
    • Grass pollens also vary by geographic location. Most of the common grass species are associated with allergic rhinitis, including Kentucky bluegrass, orchard, redtop, timothy, vernal, meadow fescue, Bermuda, and perennial rye. A number of these grasses are cross-reactive, meaning that they have similar antigenic structures (ie, proteins recognized by specific IgE in allergic sensitization). Consequently, a person who is allergic to one species is also likely to be sensitive to a number of other species. The grass pollens are most prominent from the late spring through the fall but can be present year-round in warmer climates.
    • Weed pollens also vary geographically. Many of the weeds, such as short ragweed, which is a common cause of allergic rhinitis in much of the United States, are most prominent in the late summer and fall. Other weed pollens are present year-round, particularly in warmer climates. Common weeds associated with allergic rhinitis include short ragweed, western ragweed, pigweed, sage, mugwort, yellow dock, sheep sorrel, English plantain, lamb's quarters, and Russian thistle.
  • Outdoor molds
    • Atmospheric conditions can affect the growth and dispersion of a number of molds; therefore, their airborne prevalence may vary depending on climate and season.
    • For example, Alternaria and Cladosporium are particularly prevalent in the dry and windy conditions of the Great Plains states, where they grow on grasses and grains. Their dispersion often peaks on sunny afternoons. They are virtually absent when snow is on the ground in winter, and they peak in the summer months and early fall.
    • Aspergillus and Penicillium can be found both outdoors and indoors (particularly in humid households), with variable growth depending on the season or climate. Their spores can also be dispersed in dry conditions.
• Perennial allergic rhinitis is typically caused by allergens within the home but can also be caused by outdoor allergens that are present year-round. In warmer climates, grass pollens can be present throughout the year. In some climates, individuals may be symptomatic due to trees and grasses in the warmer months and molds and weeds in the winter.
• • House dust mites
    • In the United States, 2 major house dust mite species are associated with allergic rhinitis. These are Dermatophagoides farinae and Dermatophagoides pteronyssinus.
    • These mites feed on organic material in households, particularly the skin that is shed from humans and pets. They can be found in carpets, upholstered furniture, pillows, mattresses, comforters, and stuffed toys.
    • While they thrive in warmer temperatures and high humidity, they can be found year-round in many households. On the other hand, dust mites are rare in arid climates.
  • Pets
    • Allergy to indoor pets is a common cause of perennial allergic rhinitis.
    • Cat and dog allergies are encountered most commonly in allergy practice, although allergy has been reported to occur with most of the furry animals and birds that are kept as indoor pets.
  • Cockroaches: While cockroach allergy is most frequently considered a cause of asthma, particularly in the inner city, it can also cause perennial allergic rhinitis in infested households.
  • Rodents: Rodent infestation may be associated with allergic sensitization.
• Sporadic allergic rhinitis, intermittent brief episodes of allergic rhinitis, is caused by intermittent exposure to an allergen. Often, this is due to pets or animals to which a person is not usually exposed. Sporadic allergic rhinitis can also be due to pollens, molds, or indoor allergens to which a person is not usually exposed. While allergy to specific foods can cause rhinitis, an individual affected by food allergy also usually has some combination of gastrointestinal, skin, and lung involvement. In this situation, the history findings usually suggest an association with a particular food. Watery rhinorrhea occurring shortly after eating may be vasomotor (and not allergic) in nature, mediated via the vagus nerve. This often is called gustatory rhinitis.
• Occupational allergic rhinitis, which is caused by exposure to allergens in the workplace, can be sporadic, seasonal, or perennial. People who work near animals (eg, veterinarians, laboratory researchers, farm workers) might have episodic symptoms when exposed to certain animals, daily symptoms while at the workplace, or even continual symptoms (which can persist in the evenings and weekends with severe sensitivity due to persistent late-phase inflammation). Some workers who may have seasonal symptoms include farmers, agricultural workers (exposure to pollens, animals, mold spores, and grains), and other outdoor workers. Other significant occupational allergens that may cause allergic rhinitis include wood dust, latex (due to inhalation of powder from gloves), acid anhydrides, glues, and psyllium (eg, nursing home workers who administer it as medication).

DIFFERENTIALS

Section 4 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Other Problems to be Considered

Vasomotor rhinitis or nonallergic rhinitis
Gustatory rhinitis (vagally mediated)
Rhinitis medicamentosa (eg, due to topical decongestants, antihypertensives, cocaine abuse)
Hormonal rhinitis (eg, related to pregnancy, hypothyroidism, oral contraceptive use)
Anatomic rhinitis (eg, deviated septum, choanal atresia, adenoid hypertrophy, foreign body, nasal tumor)
NARES
Immotile cilia syndrome (ciliary dyskinesis)
Cerebrospinal fluid leak
Nasal polyps
Granulomatous rhinitis (eg, Wegener granulomatosis, sarcoidosis)

WORKUP

Section 5 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Lab Studies

• Allergy testing: Testing for reaction to specific allergens can be helpful to confirm the diagnosis of allergic rhinitis and to determine specific allergic triggers. If specific allergic triggers are known, then appropriate avoidance measures can be recommended. The physician needs to know which allergens a patient is sensitive to in order to perform allergen immunotherapy (desensitization treatment). To an extent, allergy testing provides knowledge of the degree of sensitivity to a particular allergen. The most commonly used methods of determining allergy to a particular substance are allergy skin testing (testing for immediate hypersensitivity reactions) and in vitro diagnostic tests, such as the radioallergosorbent test (RAST), which indirectly measures the quantity of specific IgE to a particular antigen.
• • Allergy skin tests (immediate hypersensitivity testing) are an in vivo method of determining immediate (IgE-mediated) hypersensitivity to specific allergens. Sensitivity to virtually all of the allergens that cause allergic rhinitis (see Causes) can be determined with skin testing.
    • By introducing an extract of a suspected allergen percutaneously, an immediate (early-phase) wheal-and-flare reaction can be produced. Percutaneous introduction can be accomplished by placing a drop of extract on the skin and scratching or pricking a needle through the epidermis under the drop. Depending on the exact technique used, this testing is referred to as scratch, prick, or puncture testing. The antigen in the extract binds to IgE on skin mast cells, leading to the early-phase (immediate-type) reaction, which results in the release of mediators such as histamine (see Pathophysiology). This generally occurs within 15-20 minutes. The released histamine causes the wheal-and-flare reaction (A central wheal is produced by infiltrating fluid, and surrounding erythema is produced due to vasodilation, with concomitant itching.). The size of the wheal-and-flare reaction roughly correlates with the degree of sensitivity to the allergen.
    • The extract can also be introduced intradermally (ie, injected into the dermis with an intradermal [TB] needle). With this technique, the extract is allowed to contact the underlying dermal tissues, including skin mast cells. Intradermal testing is approximately 1000-fold more sensitive than percutaneous testing. This should be performed with care by qualified specialists. The rate of false-positive results may be high.
  • In vitro allergy tests, ie, RAST, allow measurement of the amount of specific IgE to individual allergens in a sample of blood. The amount of specific IgE produced to a particular allergen approximately correlates with the allergic sensitivity to that substance.
    • These tests allow determination of specific IgE to a number of different allergens from one blood sample, but the sensitivity and specificity are not always as good as accurate skin testing (depending on the laboratory and assay used for the RAST).
    • As with skin testing, virtually all of the allergens that cause allergic rhinitis (see Causes) can be determined using the RAST, although testing for some allergens is less well established compared to others.
  • Testing every patient for sensitivity to every allergen known is not practical. Therefore, select a limited number of allergens for testing (this applies to both skin testing and RAST). When selecting allergens, select from among the allergens that are present locally and are known to cause clinically significant allergic disease. A clinician who is specifically trained in allergy testing should select allergens for testing.
• Total serum IgE: This is a measurement of the total level of IgE in the blood (regardless of specificity). While patients with allergic rhinitis are more likely to have an elevated total IgE level than the normal population, this test is neither sensitive nor specific for allergic rhinitis. As many as 50% of patients with allergic rhinitis have normal levels of total IgE, while 20% of nonaffected individuals can have elevated total IgE levels. Therefore, this test is generally not used alone to establish the diagnosis of allergic rhinitis, but the results can be helpful in some cases when combined with other factors.
• Total blood eosinophil count: As with the total serum IgE, an elevated eosinophil count supports the diagnosis of allergic rhinitis, but it is neither sensitive nor specific for the diagnosis. The results can sometimes be helpful when combined with other factors.

Imaging Studies

• Radiography: While radiographic studies are not needed to establish the diagnosis of allergic rhinitis, they can be helpful for evaluating possible structural abnormalities or to help detect complications or comorbid conditions, such as sinusitis or adenoid hypertrophy.
• • Sinus films: A 3-view sinus series (Caldwell, Waters, and lateral views) can be helpful in evaluating for sinusitis of the maxillary, frontal, and sphenoid sinuses. The ethmoid sinuses are difficult to visualize clearly on x-ray films. Plain x-ray films can be helpful for diagnosing acute sinusitis, but CT scanning of the sinuses is more sensitive and specific. For chronic sinusitis, plain x-ray films are often inconclusive, and CT scan is much preferred.
  • Neck films: A lateral view of the neck can be helpful when evaluating for soft tissue abnormalities of the nasopharynx, such as adenoid hypertrophy.
• CT scanning: Coronal CT scan images of the sinuses can be very helpful for evaluating acute or chronic sinusitis. In particular, obstruction of the ostiomeatal complex (a confluence of drainage channels from the sinuses) can be seen quite clearly. CT scanning may also help delineate polyps, turbinate swelling, septal abnormalities (eg, deviation), and bony abnormalities (eg, concha bullosa).
• MRI: For evaluating sinusitis, MRI images are generally less helpful than CT scan images, largely because the bony structures are not seen as clearly on MRI images. However, soft tissues are visualized quite well, making MRI images helpful for diagnosing malignancies of the upper airway.

Other Tests

• Nasal cytology: A nasal smear can sometimes be helpful for establishing the diagnosis of allergic rhinitis. A sample of secretions and cells is scraped from the surface of the nasal mucosa using a special sampling probe. Secretions that are blown from the nose are not adequate. The presence of eosinophils is consistent with allergic rhinitis but also can be observed with NARES. Results are neither sensitive nor specific for allergic rhinitis and should not be used exclusively for establishing the diagnosis.

Procedures

• Rhinoscopy: While not routinely indicated, upper airway endoscopy (rhinolaryngoscopy) can be performed if a complication or comorbid condition may be present. It can be helpful for evaluating structural abnormalities (eg, polyps, adenoid hypertrophy, septal deviation, masses, foreign bodies) and chronic sinusitis (by visualizing the areas of sinus drainage).
• Nasal provocation (allergen challenge) testing: This procedure is essentially a research tool and is rarely indicated in the routine evaluation of allergic rhinitis. The possible allergen is inhaled or otherwise inoculated into the nose. The patient can then be monitored for development of symptoms or production of secretions, or objective measurements of nasal congestion can be taken. Some consider this test the criterion standard test for the diagnosis of allergic rhinitis. However, it is not a practical test to perform routinely, and only an appropriately trained specialist should perform this test.

Histologic Findings

See Other Tests.

TREATMENT

Section 6 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical Care

The management of allergic rhinitis consists of 3 major categories of treatment, (1) environmental control measures and allergen avoidance, (2) pharmacological management, and (3) immunotherapy.

• Environmental control measures and allergen avoidance: These involve both the avoidance of known allergens (substances to which the patient has IgE-mediated hypersensitivity) and avoidance of nonspecific, or irritant, triggers. Consider environmental control measures, when practical, in all cases of allergic rhinitis. However, global environmental control without identification of specific triggers is inappropriate.
• • Pollens and outdoor molds
    • Because of their widespread presence in the outdoor air, pollens can be difficult to avoid. Reduction of outdoor exposure during the season in which a particular type of pollen is present can be somewhat helpful. In general, tree pollens are present in the spring, grass pollens from the late spring through summer, and weed pollens from late summer through fall, but exceptions to these seasonal patterns exist (see Causes).
    • Pollen counts tend to be higher on dry, sunny, windy days. Outdoor exposure can be limited during this time, but this may not be reliable because pollen counts can also be influenced by a number of other factors. Keeping the windows and doors of the house and car closed as much as possible during the pollen season (with air conditioning, if necessary, on recirculating mode) can be helpful. Taking a shower after outdoor exposure can be helpful by removing pollen that is stuck to the hair and skin.
    • Despite all of these measures, patients who are allergic to pollens usually continue to be symptomatic during the pollen season and usually require some other form of management. As with pollens, avoidance of outdoor/seasonal molds may be difficult.
  • Indoor allergens
    • Depending on the allergen, environmental control measures for indoor allergens can be quite helpful. For dust mites, covering the mattress and pillows with impermeable covers helps reduce exposure. Bed linens should be washed every 2 weeks in hot (at least 130°F) water to kill any mites present. Thorough and efficient vacuum cleaning of carpets and rugs can help, but, ultimately, carpeting should be removed. The carpet can be treated with one of a number of chemical agents that kill the mites or denature the protein, but the efficacy of these agents does not appear to be dramatic. Dust mites thrive when indoor humidity is above 50%, so dehumidification, air conditioning, or both is helpful.
    • Indoor environmental control measures for mold allergy focus on reduction of excessive humidity and removal of standing water. The environmental control measures for dust mites can also help reduce mold spores.
    • For animal allergy, complete avoidance is the best option. For patients who cannot, or who do not want to, completely avoid an animal or pet, confinement of the animal to a noncarpeted room and keeping it entirely out of the bedroom can be of some benefit. Cat allergen levels in the home can be reduced with high-efficiency particulate air (HEPA) filters and by bathing the cat every week (although this may be impractical). Cockroach extermination may be helpful for cases of cockroach sensitivity.
  • Occupational allergens: As with indoor allergens, avoidance is the best measure. When this is not possible, a mask or respirator might be needed.
  • Nonspecific triggers: Exposure to smoke, strong perfumes and scents, fumes, rapid changes in temperature, and outdoor pollution can be nonspecific triggers in patients with allergic rhinitis. Consider avoidance of these situations or triggers if they seem to aggravate symptoms.
• Pharmacotherapy: See Medication.
• Immunotherapy (desensitization): A considerable body of clinical research has established the effectiveness of high-dose allergy shots in reducing symptoms and medication requirements. Success rates have been demonstrated to be as high as 80-90% for certain allergens. It is a long-term process; noticeable improvement is often not observed for 6-12 months, and, if helpful, therapy should be continued for 3-5 years. Immunotherapy is not without risk because severe systemic allergic reactions can sometimes occur. For these reasons, carefully consider the risks and benefits of immunotherapy in each patient and weigh the risks and benefits of immunotherapy against the risks and benefits of the other management options.
• • Indications: Immunotherapy may be considered more strongly with severe disease, poor response to other management options, and the presence of comorbid conditions or complications. Immunotherapy is often combined with pharmacotherapy and environmental control.
  • Administration: Administer immunotherapy with allergens to which the patient is known to be sensitive and that are present in the patient's environment (and cannot be easily avoided). The value of immunotherapy for pollens, dust mites, and cats is well established. The value of immunotherapy for dogs and mold is less well established.
  • Contraindication: A number of potential contraindications to immunotherapy exist and need to be considered. Immunotherapy should only be performed by individuals who have been appropriately trained, who institute appropriate precautions, and who are equipped for potential adverse events.

Surgical Care

Surgical care is not indicated for allergic rhinitis but may be indicated for comorbid or complicating conditions, such as chronic sinusitis, severe septal deviation (causing severe obstruction), nasal polyps, or other anatomical abnormalities. The value of turbinectomy is not established.

Consultations

While the general practitioner can effectively treat most cases of straightforward allergic rhinitis, consider consultation with an allergist or immunologist for severe disease, poor response to pharmacotherapy, and the presence of comorbid conditions or complications. Consultation with other specialists also might be needed for comorbid conditions or complications. Consult with an allergy specialist when identification or clarification of specific allergic triggers is needed, when detailed counseling regarding environmental control measures is needed, when quality of life is significantly impaired, or when immunotherapy may be a consideration.

MEDICATION

Section 7 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Most cases of allergic rhinitis respond to pharmacotherapy. Patients with intermittent symptoms are often treated adequately with oral antihistamines, decongestants, or both as needed. Regular use of an intranasal steroid spray may be more appropriate for patients with chronic symptoms. Daily use of an antihistamine, decongestant, or both can be considered either instead of or in addition to nasal steroids. The newer, second-generation (ie, nonsedating) antihistamines are usually preferable to avoid sedation and other adverse effects associated with the older, first-generation antihistamines. Ocular antihistamine drops (for eye symptoms), intranasal antihistamine sprays, intranasal cromolyn, intranasal anticholinergic sprays, and short courses of oral corticosteroids (reserved for severe, acute episodes only) may also provide relief.

Drug Category: Second-generation antihistamines

Often referred to as the nonsedating antihistamines. They compete with histamine for histamine receptor type 1 (H1) receptor sites in the blood vessels, GI tract, and respiratory tract, which, in turn, inhibits physiologic effects that histamine normally induces at the H1 receptor sites. Some do not appear to produce clinically significant sedation at usual doses, while others have a low rate of sedation. Other adverse effects (eg, anticholinergic symptoms) are generally not observed.

All are efficacious in controlling symptoms of allergic rhinitis (ie, sneezing, rhinorrhea, itching) but do not significantly improve nasal congestion. For this reason, some second-generation antihistamines are available as combination preparations containing a decongestant. They are often preferred for first-line therapy of allergic rhinitis, especially for seasonal or episodic symptoms, because of their excellent efficacy and safety profile. They can be used prn or daily.

Topical azelastine is a nasal spray antihistamine that effectively reduces sneezing, itching, and rhinorrhea but also effectively reduces congestion. Used twice per day, especially when combined with a topical nasal corticosteroid, azelastine is effective at managing both allergic and nonallergic rhinitis.

The second-generation oral antihistamines currently available in the United States are cetirizine, levocetirizine, desloratadine, fexofenadine, and loratadine. A limited number of studies comparing these agents suggest no major differences in efficacy. Only cetirizine causes drowsiness more frequently than placebo. Cetirizine, fexofenadine, and loratadine are also available in decongestant-containing preparations.

Drug Name	Levocetirizine (Xyzal)
Description	Histamine1-receptor antagonist. Active enantiomer of cetirizine. Peak plasma levels reached within 1 h and half-life is about 8 h. Available as a 5-mg breakable (scored) tab. Indicated for seasonal and perennial allergic rhinitis.
Adult Dose	5 mg PO qd in evening CrCl 50-80 mL/min: 2.5 mg (half tab) PO qd in evening CrCl 30-49 mL/min: 2.5 mg PO qod CrCl 10-29 mL/min: 2.5 mg PO 2 times/wk
Pediatric Dose	<6 years: Not established 6-12 years: 2.5 mg (half tab) PO qd in evening >12 years: Administer as in adults
Contraindications	Documented hypersensitivity; CrCl <10 mL/min or hemodialysis; children aged 6-11 y with renal impairment
Interactions	Coadministration with CNS depressants (eg, alcohol, sedative-hypnotics) may increase somnolence; ritonavir increased plasma AUC of measurable cetirizine by 42% and half-life by 53%
Pregnancy	B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions	Common adverse effects include somnolence, nasopharyngitis, fatigue, xerostomia, and pharyngitis in adults and children >12 y; pyrexia, somnolence, cough, and epistaxis commonly observed in children 6-12 y; caution with activities requiring mental alertness

Drug Name	Fexofenadine (Allegra)
Description	Second-generation agent with a rate of sedation not significantly different from that of placebo. Competes with histamine for H1 receptors in GI tract, blood vessels, and respiratory tract, reducing hypersensitivity reactions. Available in qd and bid preparations.
Adult Dose	60 mg PO bid or 180 mg PO qd
Pediatric Dose	<6 years: Not established 6-12 years: 30 mg PO bid >12 years: Administer as in adults
Contraindications	Documented hypersensitivity; in combination with pseudoephedrine, do not use if severe hypertension or coronary artery disease present; do not use within 14 d of MAOIs
Interactions	Levels may increase with coadministration of erythromycin or ketoconazole; pseudoephedrine antagonizes antihypertensives; may cause increased ectopic pacemaker activity with digitalis
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Adjust dose in renal impairment (can be used safely in hepatic impairment without dose reduction); caution in pregnancy and breastfeeding, narrow-angle glaucoma or increased intraocular pressure, mild-to-moderate hypertension, diabetes, hyperthyroidism, prostatic hypertrophy, urinary retention, seizure disorders, elderly population; anxiety or insomnia may occur because of pseudoephedrine component; can be used safely with hepatic impairment without a reduction of dose

Drug Name	Loratadine (Claritin)
Description	Selectively inhibits peripheral histamine H1 receptors. Tolerated well, with rate of sedation not significantly different from placebo.
Adult Dose	10 mg PO qd
Pediatric Dose	<2 years: Not established 2-5 years: 5 mg PO qd >5 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	Ketoconazole, erythromycin, procarbazine, cimetidine, and alcohol may increase loratadine levels; limited data exist for desloratadine; erythromycin and ketoconazole increase desloratadine and 3-hydroxydesloratadine plasma concentrations, but no increase observed in clinically relevant adverse effects, including QTc
Pregnancy	B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions	Desloratadine is pregnancy category C; initiate therapy at lower dose in liver and renal impairment; caution in pregnancy and breastfeeding; may rarely cause pharyngitis or dry mouth

Drug Name	Loratadine and pseudoephedrine (Claritin-D 24 Hour, Claritin-D 12 Hour)
Description	Tolerated well, with rate of sedation not significantly different from that of placebo. Some patients may notice anxiety or insomnia owing to pseudoephedrine component.
Adult Dose	10 mg loratadine/240 mg pseudoephedrine (Claritin-D 24 Hour): 1 tab PO qd 5 mg loratadine/120 mg pseudoephedrine (Claritin-D 12 Hour): 1 tab PO bid
Pediatric Dose	<12 years: Not established >12 years: Administer as in adults
Contraindications	Documented hypersensitivity; severe hypertension or coronary artery disease; do not use within 14 d of MAOIs
Interactions	Ketoconazole, erythromycin, procarbazine, cimetidine, and alcohol may increase loratadine levels; pseudoephedrine antagonizes antihypertensives; may cause increased ectopic pacemaker activity with digitalis
Pregnancy	B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions	Initiate therapy at lower dose in renal impairment; avoid use with hepatic impairment; caution in pregnancy and breastfeeding, narrow-angle glaucoma or increased intraocular pressure, mild-to-moderate hypertension, diabetes, hyperthyroidism, prostatic hypertrophy, urinary retention, seizure disorders, elderly population

Drug Name	Fexofenadine and pseudoephedrine (Allegra-D)
Description	Fexofenadine is a nonsedating second-generation medication with fewer adverse effects than first-generation medications. Competes with histamine for H1 receptors on GI tract, blood vessels, and respiratory tract, reducing hypersensitivity reactions. Does not sedate. Pseudoephedrine stimulates vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Induces also bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors.
Adult Dose	60 mg with 120 mg pseudoephedrine; 1 tab PO bid
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; severe hypertension or coronary artery disease; do not use within 14 d of MAOIs
Interactions	Levels may increases with coadministration of erythromycin or ketoconazole; pseudoephedrine antagonizes antihypertensives, may cause increased ectopic pacemaker activity with digitalis
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Initiate therapy at lower dose in renal impairment; caution in pregnancy and lactation; narrow-angle glaucoma or increased intraocular pressure; mild-to-moderate hypertension; diabetes; hyperthyroidism; prostatic hypertrophy; urinary retention; seizure disorders; elderly population; anxiety or insomnia may occur due to pseudoephedrine component; can be used safely with hepatic impairment without a reduction of dose

Drug Name	Desloratadine (Clarinex)
Description	Relieves nasal congestion and systemic effects of seasonal allergy. Long-acting tricyclic histamine antagonist selective for H1-receptor. Major metabolite of loratadine, which after ingestion is extensively metabolized to active metabolite 3-hydroxydesloratadine.
Adult Dose	5 mg PO qd
Pediatric Dose	<6 months: Not established 6-12 months: 1 mg PO qd 12 months to 5 years: 1.25 mg PO qd 6-12 years: 2.5 mg PO qd >12 years: Administer as in adults
Contraindications	Documented hypersensitivity to desloratadine or loratadine
Interactions	Limited data exists; erythromycin and ketoconazole increase desloratadine and 3-hydroxydesloratadine plasma concentrations, but no increase was observed in clinically relevant adverse effects including QTc
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Decrease dose in hepatic impairment; rarely causes pharyngitis or dry mouth

Drug Category: Leukotriene receptor antagonists

Alternative to oral antihistamine to treat allergic rhinitis. One of the leukotriene receptor antagonists, montelukast (Singulair), has been approved in the United States for treatment of seasonal and perennial allergic rhinitis. When used as single agent, produces modest improvement in allergic rhinitis symptoms.

Drug Category: First-generation antihistamines

The older, first-generation H1 antagonists (eg, diphenhydramine, hydroxyzine) are effective in reducing most symptoms of allergic rhinitis, but they produce a number of adverse effects (eg, drowsiness, anticholinergic effects). They can be used prn, but adverse effects may limit their usefulness when taken on a daily basis. Some patients tolerate the adverse effects with prolonged use, but they may experience cognitive impairment, and driving skills may be affected. Administration at bedtime may help with drowsiness, but sedation and impairment of cognition may continue until the next day.

The second-generation antihistamines are nonsedating in most patients and are preferred as first-line therapy. Few adverse effects are reported (cetirizine may cause drowsiness in as many as 10% of patients); therefore, many specialists prefer the use of second-generation agents for allergic rhinitis. Caution patients taking medications with sedative effects about driving and operating heavy machinery.

Drug Name	Diphenhydramine (Benadryl, Benylin)
Description	Common first-generation agent available OTC in the United States. Competes with histamine on H1-receptor sites on effector cells in blood vessels and respiratory tract. For symptomatic relief of symptoms caused by release of histamine in allergic reactions.
Adult Dose	25-50 mg PO q4-6h; not to exceed 400 mg/d
Pediatric Dose	<3 years: Not established 3-12 years: 5 mg/kg/d PO divided tid/qid; not to exceed 300 mg/d >12 years: Administer as in adults
Contraindications	Documented hypersensitivity; MAOIs
Interactions	Potentiates effect of CNS depressants; syrup contains alcohol; caution with concurrent use of medications with disulfiramlike reactions; caution with anticholinergic effects
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	May exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, urinary tract obstruction; xerostomia may occur

Drug Name	Hydroxyzine (Atarax, Vistaril, Vistazine)
Description	Effective first-generation agent but frequently produces sedation. Considerable sedation may occur with higher doses. Antagonizes H1 receptors in periphery. May suppress histamine activity in subcortical region of CNS.
Adult Dose	10-25 mg PO q6-8h
Pediatric Dose	0.6 mg/kg/dose PO q6h
Contraindications	Documented hypersensitivity
Interactions	CNS depression may increase with alcohol or other CNS depressants
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	May exacerbate porphyria (may not be safe for these patients); ECG abnormalities (alterations in T waves) may occur; may cause drowsiness; adjust dose in hepatic dysfunction

Drug Category: Decongestants

Stimulate vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Pseudoephedrine produces weak bronchial relaxation (unlike epinephrine or ephedrine) and is not effective for treating asthma. Increases heart rate and contractility by stimulating beta-adrenergic receptors. Used alone or in combination with antihistamines to treat nasal congestion. Anxiety and insomnia may occur. Expectorants may thin and loosen secretions, although experimental evidence for their efficacy is limited. Numerous preparations are available containing combinations of various decongestants, expectorants, or antihistamines. Alternatively, a separate decongestant and antihistamine can be administered to allow for individual dose titration of each drug.

Drug Category: Nasal corticosteroids

Nasal steroid sprays are highly efficacious in treating allergic rhinitis. They control the 4 major symptoms of rhinitis (ie, sneezing, itching, rhinorrhea, congestion). They are effective as monotherapy, although they do not significantly affect ocular symptoms. Studies have shown nasal steroids to be more effective than monotherapy with nasal cromolyn or antihistamines. Greater benefit may occur when nasal steroids are used with other classes of medication. They are safe to use and not associated with significant systemic adverse effects in adults (this may also be true for children, but the data are less clear).

Local adverse effects are limited to minor irritation or nasal bleeding, which resolve with temporary discontinuation of the medication. Nasal septal perforations are rarely reported and are less common with the newer corticosteroids and delivery systems. Safety during pregnancy has not been established; however, clinical experience suggests nasal corticosteroids (particularly beclomethasone, which has most experience in use) are not associated with adverse fetal effects.

The nasal steroids can be used prn, but seem to be maximally effective when used on a daily basis as maintenance therapy. They may also be helpful for vasomotor rhinitis or mixed rhinitis (a combination of vasomotor and allergic rhinitis) and can help to control nasal polyps.

Drug Name	Beclomethasone (Beconase, Beconase AQ, Vancenase Pockethaler, Vancenase AQ)
Description	Older topical nasal steroid. Most reliable during pregnancy, as it has been in use for many years with no significant problems observed. May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.
Adult Dose	1-2 puffs/nostril (42 mcg/puff) qd/bid; titrate to lowest effective dose Vancenase AQ Double Strength (84 mcg/puff): 1-2 puffs/nostril qd; titrate to lowest effective dose
Pediatric Dose	<6 years: Not established >6 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	None reported
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Monitor for growth suppression in children; caution in pregnancy and breastfeeding

Drug Name	Budesonide (Rhinocort Aqua)
Description	Newer topical steroid considered efficacious and safe for allergic rhinitis. May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.
Adult Dose	1-4 puffs/nostril (32 mcg/puff) qd or divided bid; titrate to lowest effective dose
Pediatric Dose	<6 years: Not established 6-12 years: 1-2 puffs/nostril qd or divided bid; titrate to lowest effective dose >12 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	None reported
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Monitor for growth suppression in children; caution in pregnancy and breastfeeding

Drug Name	Fluticasone (Flonase)
Description	Newer topical steroid considered efficacious and safe for allergic rhinitis. May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.
Adult Dose	1-2 puffs/nostril (50 mcg/puff) qd or 1 puff/nostril bid; titrate to lowest effective dose; not to exceed 4 puffs/d (200 mcg)
Pediatric Dose	<4 years: Not established >4 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	None reported
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Monitor for growth suppression in children; caution in pregnancy and breastfeeding; nosebleeds may occur

Drug Name	Ciclesonide (Omnaris)
Description	Corticosteroid nasal spray indicated for allergic rhinitis. Prodrug that is enzymatically hydrolyzed to pharmacologic active metabolite C21-desisobutyryl-ciclesonide following intranasal application. Corticosteroids have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, cytokines) involved in allergic inflammation. Each spray delivers 50 mcg.
Adult Dose	2 sprays (50 mcg/spray) in each nostril qd (ie, 200 mcg/d)
Pediatric Dose	<12 years: Not established >12 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	Data limited; oral ketoconazole increases desciclesonide AUC by approximately 3.5-fold at steady state
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	Caution when replacing systemic corticosteroids because of risk of adrenal insufficiency; may decrease growth velocity in pediatric patients; caution with active or quiescent tuberculosis infection or with untreated fungal, viral, or bacterial infections; rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure reported

Drug Name	Fluticasone furoate (Veramyst)
Description	Intranasal corticosteroid. Indicated for seasonal and perennial allergic rhinitis. Relieves nasal symptoms associated with allergic rhinitis. Has also demonstrated improvement in allergic eye symptoms. Contains 27.5 mcg/spray.
Adult Dose	110 mcg intranasally qd initially (ie, 2 sprays each nostril qd); once symptoms improve, may decrease to 55 mcg qd (ie, 1 spray each nostril qd)
Pediatric Dose	<2 years: Not established 2-12 years: 55 mcg intranasally qd (ie, 1 spray each nostril qd) >12 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	Coadministration with other corticosteroids could increase risk of hypercorticism and/or suppression of HPA; coadministration with CYP450 3A4 isoenzyme inhibitors (eg, amprenavir, atazanavir, darunavir, delavirdine, fosamprenavir, indinavir, ketoconazole, nelfinavir, ritonavir, tipranavir) decreases fluticasone elimination and increases plasma fluticasone levels
Pregnancy	B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions	Prime before using for first time by shaking contents and releasing 6 test sprays into air away from face; common adverse effects include headache, nose bleed, and nasal sores; fever occurred more frequently in children aged 2-11 years compared to placebo; epistaxis or sensations of nasal burnings may occur; local candidal infections of nasopharynx have been reported with topical steroid use; always consider potential risk of suppression of HPA when using large dose for prolonged periods; rare cases of cataract, glaucoma, and increased intraocular pressure have been reported following intranasal use of corticosteroids; concomitant use of intranasal corticosteroids and other inhaled and/or systemically absorbed corticosteroids may cause hypercorticism and/or HPA suppression; if exposed to measles or chickenpox, consider prophylactic therapy

Drug Name	Triamcinolone (Nasacort AQ)
Description	Injectable corticosteroid used to treat inflammatory dermatosis responsive to steroids; decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.
Adult Dose	0.5 cc into each inferior turbinate q6-8wk
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; fungal, viral, and bacterial skin infections
Interactions	None reported
Pregnancy	C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions	A percentage of topical drug might be absorbed systemically; if application is repeated, some systemic effects of the corticosteroids may occur

Drug Category: Intranasal antihistamines

Alternative to oral antihistamines to treat allergic rhinitis. Currently, azelastine is only agent available in the United States.

Drug Category: Intranasal cromolyns

Produce mast cell stabilization and antiallergic effects that inhibit degranulation of mast cells. Have no direct anti-inflammatory or antihistaminic effects. Effective for prophylaxis. May be used just before exposure to a known allergen (eg, animal, occupational). Begin treatment 1-2 wk before pollen season and continue daily to prevent seasonal allergic rhinitis. Effect is modest compared with that of intranasal corticosteroids. Excellent safety profile and are thought to be safe for use in children and pregnancy.

Drug Category: Intranasal anticholinergic agents

Used for reducing rhinorrhea in patients with allergic or vasomotor rhinitis. No significant effect on other symptoms. Can be used alone or in conjunction with other medications. In the United States, ipratropium bromide (Atrovent Nasal Spray) is available in a concentration of 0.03% (officially indicated for treatment of allergic and nonallergic rhinitis) and 0.06% (officially indicated for the treatment of rhinorrhea associated with common cold). The 0.03% strength is discussed.